Skip to content

Comparison of the Aspen Device Versus Pedicle Screws for Supplemental Posterior Fixation in Lumbar Interbody Fusion

A Multi-Center Prospective Randomized Study Comparing Supplemental Posterior Instrumentation, Aspen™ Spinous Process System Versus Pedicle Screw Fixation, in Lateral Lumbar Interbody Fusion (LLIF) or Anterior Lumbar Interbody Fusion (ALIF)

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT01549366
Enrollment
64
Registered
2012-03-09
Start date
2012-02-29
Completion date
2016-01-31
Last updated
2018-03-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Degeneration of Lumbar Intervertebral Disc

Brief summary

The purpose of this clinical investigation is to evaluate the Aspen™ device compared to pedicle screw instrumentation for posterior fixation in the treatment of patients with degenerative disc disease and/or spondylolisthesis. The Aspen™ device will be compared to pedicle screw instrumentation in Oswestry Disability Index (ODI) improvement and success of fusion.

Detailed description

This is a multi-center, prospective randomized clinical study to evaluate the clinical outcome of subjects with degenerative disc disease (DDD) (defined as back pain of discogenic origin with degeneration of the disc confirmed by history and radiographic studies) and/or spondylolisthesis utilizing either Aspen Spinous Process Fixation System or Pedicle Screws for supplemental posterior instrumentation as an adjunct to an anterior or lateral approach to lumbar interbody fusion. The primary hypothesis is that change in Oswestry Disability Index (ODI) of subjects in the study group (Aspen) will be non-inferior to the control group (pedicle screw instrumentation). The non-inferiority margin is pre-specified to be 10 ODI score points. If the non-inferiority is established, superiority of Aspen to the control will be tested. The study will involve up to 25 investigational sites. Enrollment is expected to take approximately 24 months. Subjects will be followed for 2 years, with the anticipated duration of the study being approximately 4 years from start to finish.

Interventions

The Aspen device will be placed as posterior fixation to Lateral Lumbar Interbody Fusion (LLIF) or Anterior Lumbar Interbody Fusion (ALIF)

Pedicle Screws will be placed as posterior fixation to Lateral Lumbar Interbody Fusion (LLIF) or Anterior Lumbar Interbody Fusion (ALIF)

Sponsors

Zimmer Biomet
Lead SponsorINDUSTRY

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to 75 Years
Healthy volunteers
No

Inclusion criteria

* Age between 18 and 75 years * Scheduled for an elective single-level circumferential lumbar fusion by means of supplemental posterior fusion with fixation (allowing for the placement of ASPEN or pedicle screws) for an anterior or lateral interbody fusion * Diagnosis of primary symptomatic Degenerative Disc Disease (DDD) and/or spondylolisthesis confirmed with appropriate imaging studies and/or positive lumbar discography * Oswestry Disability Index (ODI) v2.1 score \> 30% * Failed at least 3 months of conservative care (non-surgical) OR has clinical signs of neurological deterioration * Signed Informed Consent Form

Exclusion criteria

* Previous fusion at the operative level * Spondylolisthesis Grade 3 or more * Lytic spondylolisthesis * Incompetent or missing posterior arch at the affected level (e.g. complete laminectomy, pars defect) * Requires complete laminectomy at level of surgery * Facet joints at implant level are absent or fractured * Vertebral body compromise or acute fracture at implant level * Body mass Index (BMI) ≥ 35 * Known allergy to titanium * Osteoporosis: Simple Calculated Osteoporosis Risk Estimation (S.C.O.R.E.) \> 6 AND Dual-energy X-ray absorptiometry (DEXA) T-score \< -2.5 * Paget's disease, osteomalacia, or any other metabolic bone disease * Use of medications or any drug known to potentially interfere with bone/soft tissue healing (e.g. chronic systemic steroids) * Planned use of additional segmental fixation (eg. facet screws) * Planned use of Bone Morphogenetic Protein (BMP) for posterolateral fusion\* * Unlikely to comply with the follow-up evaluation schedule * In the opinion of the Investigator, Subject has history of chemical substance dependency or significant psychosocial disturbance that may impact the outcome or study participation * Active participation in a clinical trial of another drug or device * Active systemic infection or any other health condition that would preclude surgery * History of invasive malignancy, except if the subject has received treatment and displayed no clinical signs and symptoms for at least five years * Subject is a prisoner * Pregnant or planning to become pregnant during the length of study participation * Involvement in active litigation related to back problems at the time of screening * Direct involvement in the execution of this protocol * Pre-existing conditions that could interfere with the evaluation of outcome measures (e.g. musculoskeletal, neuromuscular, etc.)

Design outcomes

Primary

MeasureTime frame
Absolute change in Oswestry Disability Index (ODI)baseline to 12 months post-operative

Secondary

MeasureTime frame
Neurological statusBaseline, 6 weeks, 3 months, 6 months, 12 months, & 24 months
Change in EQ-5D-3LBaseline, 6 weeks, 3 months, 6 months, 12 months, & 24 months
Change in SF-36Baseline, 12 months & 24 months
Fusion success12 months and 24 months
Change in Zurich Claudication QuestionnaireBaseline, 12 months & 24 months
Pain medication usageBaseline, surgery, 6 weeks, 3 months, 6 months, 12 months, & 24 months
Operative parameters (estimate blood loss, fluor time, length of hospital stay)Intraoperative
Change in Visual Analogue Scale (VAS) (pain)Baseline, 6 weeks, 3 months, 6 months, 12 months, & 24 months

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026